Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2024-04-21 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
独立董事关于控股股东及其他关联方占用公司资金、对外担保情况的专项说明和独立意见
Audit Report / Information Classification · 95% confidence The document is a special statement and independent opinion from independent directors regarding the company's related party fund occupation and external guarantees for the year 2023. It references regulatory notices from the China Securities Regulatory Commission and Shenzhen Stock Exchange guidelines. The content is focused on compliance and independent verification rather than presenting financial statements or audit results. The document length is short (636 characters), and it is a formal opinion statement rather than a full audit report or annual report. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to internal or regulatory compliance, excluding full annual reports. FY 2023
2024-04-21 Chinese
2023年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2023年度监事会工作报告" which translates to "2023 Supervisory Board Work Report". It details the supervisory board's activities, meetings, oversight on financials, internal controls, compliance with laws, and plans for 2024. The content is a formal report from the supervisory board summarizing their work and oversight during the year 2023. It is not an annual report (10-K), audit report (AR), or interim report (IR) but a specific supervisory board work report. This type of document is typically classified under Management Reports (MDA) as it provides management's detailed explanation of company oversight, financial results, business trends, and outlook. The document length is 3276 characters, which is sufficient for a detailed report but not a brief announcement. Therefore, the best fitting category is Management Reports (MDA).
2024-04-21 Chinese
信永中和会计师事务所（特殊普通合伙）关于恩威医药2023年度募集资金年度存放与使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "募集资金存放与实际使用情况 鉴证报告" which translates to "Verification Report on the Deposit and Actual Use of Raised Funds" for the year 2023. It includes detailed financial data about the raised funds, their deposit, usage, interest income, and compliance with regulatory requirements from the Shenzhen Stock Exchange and China Securities Regulatory Commission. The document is prepared by the company's board and audited by a CPA firm, indicating it is a specialized report on the use of capital raised by the company. This type of report is a specialized audit or assurance report on capital usage, not a full annual or interim financial report. It is not an announcement or a brief summary but a detailed verification report. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and results related to capital usage verification, excluding full annual reports or interim reports. FY 2023
2024-04-21 Chinese
独立董事2023年度述职报告（漆小川）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2023 Annual Work Report" for Enwei Pharmaceutical Co., Ltd. It details the independent director's duties, attendance at board and shareholder meetings, opinions on major company matters, supervision of related party transactions, external guarantees, remuneration, use of raised funds, and internal controls for the year 2023. The content is a detailed report of the independent director's activities and opinions over the year, which is a typical form of a management or board-related report rather than a full annual report or audit report. It is not a simple announcement or certification but a substantive report on the director's work and oversight. This fits best under the category of Board/Management Information (MANG), which covers announcements of changes or reports related to the company's board or senior management activities. The document is over 5,000 characters and contains detailed content, so it is not a mere announcement (RPA) or regulatory filing (RNS).
2024-04-21 Chinese
2023年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 90% confidence The document is a summary table detailing the 2023 non-operating fund occupation and other related party fund transactions for a listed company, including amounts at the beginning and end of the year, and related party names. It contains financial data but is very short (2960 characters) and appears to be a specific financial disclosure related to related party transactions rather than a full financial report. It does not resemble an annual report, interim report, or earnings release. It is not a regulatory announcement or certification. Given the nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not neatly fit into other categories but involve regulatory disclosures.
2024-04-21 Chinese
中信证券股份有限公司关于恩威医药股份有限公司2023年度内部控制自我评价报告的核查意见
Regulatory Filings Classification · 95% confidence The document is titled as an internal control self-evaluation report verification opinion by CITIC Securities for Enwei Pharmaceutical Co., Ltd. for the year 2023. It discusses the internal control evaluation, defect recognition standards, and the verification work done by the sponsor institution. The document is a verification opinion on the internal control self-evaluation report, not the report itself. It is relatively short (3295 characters) and appears to be a formal opinion or certification related to the internal control report rather than the full report or financial statements. This fits best with the category of Regulatory Filings (RNS), which includes certifications, attestations, and related regulatory documents that do not constitute full reports themselves.
2024-04-21 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.